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Abstract 
Purpose:  Sodium  stibogluconate  (SSG),  a  small  molecule  inhibitor  of  protein  tyrosine 
phosphatases, combined with IFN-alpha-2b (IFN-α) inhibited solid tumor cell line growth in 
vitro. We conducted a phase I clinical trial with SSG plus IFN-α in advanced cancer patients to 
assess tolerance, maximum tolerated dose (MTD) and immune system effects. 
Experimental Design: SSG was administered intravenously alone for five days of week 1, 
cycle 1 (21 days per cycle) and together with IFN-α 2b s (3 million units sc TIW) in week 2, 
and after a rest during week 3, on a 2-week on/1-week off cycle. SSG dose levels were 400, 
600, 900, 1125, and 1350 mg/m
2.  
Results: Twenty-four patients were studied. Common toxicities included asymptomatic 
elevated serum lipase, thrombocytopenia, fatigue, fever, chills and anemia. The dose-limiting 
toxicities (DLT) were hypokalemia, thrombocytopenia, fatigue, pancreatitis and skin rash. The 
MTD was 900 mg/m
2 SSG and IFN-α, 3 million units TIW. At this dose, patients had a sig-
nificantly lower number of regulatory T cells (TR Cells) (p = 0.012), myeloid dendritic cells 
(mDC) (p = 0.028); higher percentage of natural killer (NK) cells that synthesized perforin (p 
= 0.046) and of plasmacytoid dendritic cells (pDC) that secreted IFN-α (p = 0.018) in re-
sponse to activation through toll-like receptor (TLR) 7 and TLR 8 by CL097, the highly wa-
ter-soluble derivative of the imidazoquinoline compound R848.  
Conclusions: SSG in combination with IFN-α 2b was well tolerated and augmented cellular 
immune parameters. 
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INTRODUCTION 
Sodium stibogluconate (SSG), a small molecule 
inhibitor of protein tyrosine phosphatases (PTPases) 
[1],  has  been  used  extensively  for  the  treatment  of 
human leishmaniasis [2,3] and preclinically with de-
monstrable activity against a murine melanoma cell 
line [3]. SSG putatively interferes with SHP-1, so that Journal of Cancer 2011, 2 
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IFN-alpha (IFN-) remains in the “on” state and in-
hibits tumorigenesis [4]. IFN- 2b is FDA-approved 
for treating solid tumors such as malignant melanoma 
[5]  and  AIDS-related  Kaposi’s  sarcoma  [6],  and  he-
matologic malignancies such as aggressive follicular 
non-Hodgkin’s lymphoma and chronic myelogenous 
leukemia [7]. However, tumor cell resistance and side 
effects  often  limit  its  clinical  efficacy,  which  is  ex-
pected to improve at a lower dose and  when com-
bined with other therapeutic agents [8,9].  
The  combination  of  SSG  and  IFN  -2b  was 
shown to be effective against larger WM9 tumors in 
mice and was well tolerated in a long-term treatment 
course [1]. These preclinical observations suggested an 
important potential for PTPase inhibitors to improve 
the efficacy of IFN -2b. Sodium stibogluconate is an 
ideal drug to evaluate as an antineoplastic agent in 
combination  with  IFN  -2b.  We  hypothesized  that 
combining  SSG  and  IFN-  2b  would  modulate 
host-immune defense mechanisms and enhance anti-
tumor activity in cancer patients with tumors known 
to be responsive to IFN- therapy. Our goals in this 
phase I, dose-findin g study were to investigate the 
synergistic antitumor activity of  the combination  of 
SSG and IFN- 2b, delineate the toxicity profile, es-
tablish the maximum tolerated dose (MTD), and im-
mune effects in cancer patients.  
PATIENTS AND METHODS   
Patient eligibility and selection 
Inclusion  criteria  included  metastatic or  locally 
advanced solid cancers not responsive to conventional 
therapy  with  no  established life-prolonging  therapy 
available; age ≥18 years; Eastern Cooperative Oncol-
ogy Group (ECOG) (performance status 0–2; adequate 
bone marrow; adequate hepatic status, renal function 
(creatinine ≤1.5 mg/dL) and cardiac function (ejection 
fraction  >50%);  no  chemotherapy or  radiotherapy  3 
weeks before study entry. Exclusion criteria included 
concurrent immunotherapy, no recovery from acute 
toxicity of previous therapy, medically uncontrolled 
cardiovascular  illness,  electrocardiogram  anomalies 
suggestive  of  cardiac  conduction  delay  (QTc  >  0.47 
seconds),  past  clinically  significant  cardiac  arrhyth-
mias, symptomatic or untreated central nervous sys-
tem  metastases  and  history  of  hypersensitivity  to 
IFN-α 2b or SSG or their components.  
Treatment/study plan 
Sodium stibogluconate (Lenocta™) was supplied 
by  VioQuest  Pharmaceuticals,  Inc.  (Basking  Ridge, 
NJ).  Prior  to  enrollment,  patients  signed  a  written, 
informed  consent  in  accordance  with  NCI  require-
ments, the MD Anderson Cancer Center Institutional 
Review  Board  and  the  University  of  New  Mexico 
(UNM) School of Medicine Human Research Review 
Committee policies.  
Cohorts of 3 patients each were enrolled using a 
standard phase I, 3+3 study design. Each cycle con-
sisted of 21 days. During the first week of cycle 1, pa-
tients received SSG alone intravenously (IV) over 15 
minutes for 5 days (Monday through Friday) (Figure 
1). In week 2, cycle 1, patients received SSG IV for 5 
days  (Monday  through  Friday),  along  with  3x106 
units of IFN- 2b subcutaneously (SQ) three times a 
week (Monday, Wednesday, Friday). Week 3, cycle 1, 
was a rest period. During cycle 2 and subsequent cy-
cles, patients received SSG IV for 5 days and IFN- 2b 
SQ thrice  weekly for the first and second  weeks  of 
each cycle. The SSG dose was escalated in successive 
cohorts,  with  no  escalation  within  cohorts.  Cycles 
continued until disease progression or dose-limiting 
toxicities(s) (DLT). 
 
 
 
Figure 1. Study design and treatment regimen. SSG 
was administered daily as a monotherapy during the first 
week of cycle 1. Peripheral blood samples were collected 
prior to therapy on the second week of cycle 1 (C1D8) to 
evaluate the effect of SSG. IFN-α 2b was administered 3 
times  per  week  beginning  the  second  week  of  cycle  1. 
Peripheral blood samples were collected at the end of 2 
cycles (C2D12) to evaluate the effect of SSG + IFN-α 2b 
combination therapy. 
 
 
Toxicity in each group of 3 patients treated with 
different dosage levels was graded according to the 
Common  Terminology  Criteria  for  Adverse  Events 
(CTCAE), version 3.0, at the end of each cycle. Even 
though the traditional definition of DLTs within the 
first cycle was initially used, we later extended our 
DLT window to cycle 2 as the cycles were relatively 
short and only SSG was given during the first week of 
the first cycle. DLT was defined as any one or more of Journal of Cancer 2011, 2 
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the following events considered related to treatment 
with study drug that were grade >3: non-hematologic 
toxicity,  grade  4  hematologic  toxicity  (neutropenia, 
anemia or thrombocytopenia), prolongation of QTc to 
>0.47 seconds, grade 2 or greater cardiovascular ar-
rhythmia,  and/or  ECG  changes  associated  with  T 
wave  inversion  with  ST  segment  depression,  any 
grade 4 pancreatic enzyme elevation that lasted long-
er than 8 days or that was accompanied by clinical 
symptoms of pancreatitis.  
A grade 3 non-hematologic toxicity or grade 4 
hematologic toxicity was considered a DLT only after 
delivery  of  maximum  supportive  care.  Important 
medical  events  other  than  those  listed  above  were 
considered  a  DLT  based  upon  appropriate  medical 
judgment and following discussion among the inves-
tigators and the VioQuest medical monitor. 
Dose escalation 
The starting dose of SSG was 400 mg/m2/day 
administered daily IV over 15 minutes. With no sig-
nificant toxicity, the dose for subsequent cohorts was 
increased by 50% of the preceding dose. If DLTs oc-
curred, the dose in subsequent cohorts was increased 
by only 25% of the preceding dose. Cohorts of at least 
3  patients  were  treated  at  each  dose  level  until  the 
MTD was defined. If 1 of 3 patients had a DLT, the 
cohort was expanded to a maximum of 6 patients. If 
only 1 of those 6 patients experienced a DLT, the dose 
for  subsequent  cohorts  was  escalated  by  25%.  If  at 
least 2 patients in a cohort had DLTs, no dose escala-
tion was permitted. The dose level at which 2 of 6 
patients experienced a DLT was considered one dose 
level above the MTD. Table 1 shows the dose escala-
tion scheme for this study. 
 
Table 1: Dose Escalation Schedule for SSG and Fixed Dose 
of IFN- 2b (3 x 10
6 units) (N = 24 patients) 
Dose of SSG (mg/m2)  N =   DLTs 
400   3  0 
600  5  0 
900 (expansion co-
hort) 
8  0 
1125  4  3 (symptomatic pancreatitis and 
thrombocytopenia) 
1350  4  2 (hypokalemia, thrombocytopenia, 
fatigue and skin rash) 
 
Duration of therapy 
Patients remained on protocol until disease pro-
gression,  unacceptable  adverse  events,  concurrent 
illness preventing further administration of drug, or if 
they had stable disease (SD), a partial response (PR), 
or a complete response (CR) to treatment, and if there 
was an acceptable toxicity profile. Patients were taken 
off study for therapy-related intolerable toxicity, pro-
gressive  disease,  or  self-election  to  withdraw  from 
study. 
Clinical response  
All patients underwent imaging with computed 
tomography  (CT)  scans  and/or  positron  emission 
tomography (PET), and disease-specific tumor mark-
ers  whenever  applicable.  Evaluation  for  treatment 
response was done every six weeks using Response 
Evaluation Criteria in Solid Tumors (RECIST) criteria 
[10]. 
Immune monitoring of patients 
Patients were assessed prior to initiation of SSG 
therapy,  cycle  1,  day  1  (C1D1),  at  the  end  of  SSG 
monotherapy (C1D5) and prior to addition of IFN- 
on  C1D8,  at  the  end  of  the  combination  therapy 
(C1D12), and on C2D12. On days of assessment, pa-
tients provided 27 mL of peripheral blood for immune 
evaluation  that  included  leukocyte  immunopheno-
typing, cytokine syntheses by individual T cells acti-
vated  through  the  T-cell  receptor  (TCR)  using  an-
ti-CD3  antibodies  and  by  toll-like  receptor 
(TLR)-activated  dendritic  cells  (DC);  expression  of 
granzyme  B  and  perforin  A  by  natural  killer  (NK), 
natural killer T (NKT) cells, and CD8+ T cells.  
Enumeration of leukocyte subsets by flow cy-
tometry  
Subsets of T cells (CD4, CD8, and T-regulatory 
(TR)),  B-cells  (CD19),  and  NK  cells  (CD56/16)  cells 
were determined as previously described [11].  
Perforin A and Granzyme A expression by NK 
and NKT cells 
Briefly,  peripheral  blood  lymphocytes  were 
stained for cell surface markers CD3, CD16+56, and 
CD8 as previously described [11], then permeabilized 
with BD CytoFix/CytoPerm according to the manu-
facturer’s recommended procedures and stained with 
FITC  conjugated  antibodies  against  granzyme  A, 
perforin or the appropriate isotype-matched control 
immunoglobin, and analyzed using 6-parameter flow 
cytometry.  Perforin  and  granzyme  expression  was 
recorded  as  percentage  of  CD16/56+  (NK)  or 
CD3+16/56+ (NKT) lymphocytes with fluorescent in-
tensity of the perforin or granzyme antibodies greater 
than isotype-matched control antibodies.  
Cytokine synthesis by anti-CD3 activated T cells  
Intracellular  cytoplasmic  interleukin  (IL)-2, 
IL-10, interferon-gamma (IFN-), and tumor necrosis 
factor-alpha  (TNF-)  by  TCR-activated  T  cells  were Journal of Cancer 2011, 2 
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measured by a flow cytometric assay as previously 
described [12].  
Quantification of circulating DCs 
Subsets  of  myeloid  DCs  (mDC/DC1)  and 
plasmacytoid DCs (pDC/DC2) were enumerated as 
previously reported [13].  
 
Cytokine synthesis by mDC and pDC activated 
through TLR 
Cytokine  synthesis  by  DCs  stimulated  with  10 
µM of CL097, a highly water-soluble derivative of the 
imidazoquinoline  compound  R848  (Invivogen,  San 
Diego, CA), was performed as previously described 
[14]. Similar to R848, CL097 is a TLR7 and TLR8 lig-
and that induces cytokine syntheses in DCs through 
the activation of the NF-κB [15,16].  
Statistical analysis 
Descriptive  statistics  were  used  for  the  patient 
treatment description. Due to small sample size and 
non-normal  distribution  of  cytokine  production, 
nonparametric  tests  compared  median  values  for 
immunologic  analysis.  The  Friedman  test  assessed 
significant  rank  differences  in  phenotype  and  cyto-
kine measures over the study period followed by the 
Wilcoxon  signed-rank  test  of  paired  samples  to  de-
termine  differences  between  specific  time  points  in 
therapy. The Mann-Whitney U test analyzed differ-
ences among different treatment arms, i.e., low-dose 
SSG  (<900  mg/m2)  and  high-dose  (≥900  mg/m2). 
Graphs were plotted as mean plus or minus standard 
error to show central tendency and variance. 
RESULTS 
Patient characteristics 
Twenty-four  patients  (13  men  and  11  women) 
participated in this phase I study (median age of 59.5 
years; range, 37-82). Nine patients had an ECOG per-
formance status of 0, and 15 patients had an ECOG of 
1. Prior therapies varied from 1 to 10 regimens (me-
dian,  4).  Various  solid  tumors  were  included;  most 
commonly melanoma, pancreatic and colorectal (Ta-
ble 2).  
Dose escalation and MTD 
Within the SSG 900 mg/m2 cohort, one patient 
progressed during cycle 1 and was replaced. Because 
three evaluable patients tolerated the 900 mg/m2 SSG 
dose, it was increased to 1350 mg/m2, and two pa-
tients experienced DLTs. The first patient with DLT 
had a grade 4 hypokalemia and a grade 4 thrombo-
cytopenia  (which  did  not  return  to  baseline  after 
platelet  transfusion).  The  second  patient  with  DLT 
had  grade  3  fatigue  and  grade  3  skin  rash.  Subse-
quently, an intermediate dose of SSG of 1125 mg/m2 
was tested. One patient in this cohort had a grade 2 
DLT  of  clinically  symptomatic  pancreatitis  and  the 
cohort  was  expanded.  Two  additional  patients  had 
grade 2 pancreatitis and grade 4 thrombocytopenia. 
Thus, the MTD was set at 900 mg/m2. The cohort was 
expanded  to  total  of  8  patients.  No  DLTs  were  ob-
served. 
Table 2: Patient Characteristics (N = 24)  
Total Pts    24        
Median Age  59.5       
Range  37-82       
Male  13       
Female  11       
         
Race         
White  22       
Asian  1       
Hispanic  1       
         
ECOG         
PS= 0  9       
PS=1  15       
         
Media Prior Regimens  4       
Max  10       
Min  1       
         
Diagnosis  Number  %  Dosage  Patients 
 
Melanoma 
7  29  400  3 
Pancreatic  4  17  600  5 
Colorectal  3  13  900  8 
Adenocystic H&N  2  8  1125  4 
Mesothelioma  1  4  1350  4 
Prostate  1  4     
Neuroendrocrine  1  4  Total  24 
Ovarian  1  4     
Squamous Cell H&N  1  4     
Granulosa Cell  1  4     
Merkel Cell  1  4     
Angiosarcoma  1  4     
         
Total  24  99     
PS , performance status; ECOG, Eastern Cooperative Oncology 
Group; H&N, head and neck 
 
Safety/Toxicity 
Adverse  events  are  shown  in  Table  3.  Despite 
elevated  serum  amylase  (n=7)  and/or  lipase  (n=16) 
levels  occurring  frequently,  most  patients  were 
asymptomatic; two had clinically significant grade 2 
pancreatitis. Fourteen patients completed two cycles 
and  were  restaged.  One  patient  with  advanced  re-
fractory colorectal cancer in the 600 mg/m2 SSG co-
hort received cycle 3, but withdrew from the study. Journal of Cancer 2011, 2 
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The second patient with adenocystic carcinoma in the 
1350  mg  /m2  SSG  cohort,  also  with  SD,  withdrew 
from  the  study  due  to  non-DLT  side  effects  and 
treatment schedule. A third patient with ocular mel-
anoma in the 400 mg /m2 SSG cohort had SD after two 
cycles,  but  withdrew  from  treatment.  The  other  11 
patients  had  progressive  disease  at  restaging  at  the 
end of cycle 2. Although there was no clinically ob-
servable  anticancer  activity  in  this  study,  SSG  had 
significant effects on host-immune responses.  
Table 3: Drug Related Common Side Effects 
    Side Effects at Different Dose Levels 
  TOTAL DLTS  400 mg/m2  600 mg/m2  900 mg/m2  1125 mg/m2  1350 mg/m2 
Grade  1-2  3  4  1-2  3  4  1-2  3  4  1-2  3  4  1-2  3  4  1-2  3  4 
Nausea  6  0  0  1      1      2      1      1     
Vomiting  4  0  0  1            1      1      1     
Chills  9  1  0  2      4      1      1      1  1   
Fatigue  7  4  0  2  1    3      1  1      1    1  1   
Fever  10  1  0  1      5      2      1      1  1   
Myalgia  3  0  0        2                  1     
Rash  1  1  0                    1        1   
Anorexia  5  1  0        1      2  1    1      1     
Lymphopenia  4  0  0        4                       
Leukocytes  4  1  0        1      1  1          2     
Neutrophils  5  0  0        1      2            2     
Platelets  3  5  3          1    3  1        2    3  1 
Hemoglobin  3  7  0    1          1  5          2  1   
Amylase  3  4  0  1      1  1    1  1      1      1   
Lipase  4  7  5      1  1  2  1  2  3  1      1  1  2  1 
Potassium, Serum Low  2  4  2              1  2  1    2    1    1 
Pancreatitis  2  0  0                    2           
 
 
Enumeration of leukocyte subsets by flow cy-
tometry  
Seventeen patients were evaluated for immune 
studies. For the immunology data analysis, patients 
who received SSG <900 mg/m2 (n=8) were defined as 
the low-dose SSG cohort, and patients who received a 
dose of SSG ≥900 mg/m2 were defined the high-dose 
SSG cohort (n=9).  
Initially,  the  effect  of  SSG  monotherapy,  C1D1 
vs. C1D8, and the effect of SSG in combination with 
IFN- (C1D8 vs. C2D12) were assessed in all patients. 
After SSG monotherapy, median %TR cells (p = 0.022) 
(Figure 2), median %mDC (p = 0.003) (Figure 3A) and 
median  %pDC  (p  =  0.022)  (Figure  3B)  significantly 
decreased, but following combination therapy median 
%mDC (p = 0.041) significantly increased (Figure 3A). 
In  patients  receiving  low-dose  SSG  monotherapy, 
there  were  statistically  significant  reductions  in  the 
median %CD4+ T cells (43.7% vs. 41.1%, p = 0.036) and 
median %TR cells (2.5% vs. 2.0%, p = 0.017), but sta-
tistically  significant  increases  in  median  %NK  cells 
(17.6%  vs.  22.3%,  p  =0.05).  Following  combination 
therapy  the  median  %mDC  increased  (47.8%  vs. 
58.3%,  p  =  0.028).  However,  in  patients  receiving 
high-dose SSG there were no statistically significant 
changes  in  median  %CD4+  T  (49.0%  vs.  49.9%,  p  = 
0.575), median %TR cells (3.4% vs. 3.0%, p = 0.444), 
and median %NK cells (16.6% vs. 14.4%, p = 0.721). 
Following  combination  therapy  the  median  %mDC 
increased in patients receiving low-dose SSG (47.8% 
vs. 58.3%, p = 0.028), and although there was a similar 
trend in patients receiving high-dose SSG, it was not 
statistically significant (45.0% vs. 55.0%, p = 0.893).  
 
Figure  2  Differences  in  the  percentage  of 
CD4+CD25
hi  TR  cells. Fresh peripheral blood samples 
were  evaluated  by  flow  cytometry  for  the  presence  of 
CD3
+CD4
+CD25
hi  TR  cells  at  baseline,  following  SSG 
monotherapy  (C1D8),  and  following  SSG  +  IFN-α  2b 
combination  therapy  (C2D12).  There  was  a  significant 
decrease in the percentage of CD3
+CD4
+CD25
hi TR cells 
following SSG monotherapy. Journal of Cancer 2011, 2 
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Figure 3 Differences in the percentage of dendritic cells. Fresh peripheral blood samples were evaluated by flow 
cytometry for the presence of Lin
-HLA-DR
+ dendritic cells at baseline, following SSG monotherapy (C1D8) and following 
SSG + IFN-α combination therapy (C2D12). (A) Following SSG monotherapy, there was a transient decrease in the per-
centage of CD11c
+CD123
- mDC within the Lin
-HLA-DR
+ population followed by a significant increase with the addition of 
IFN-α 2b. (B) The percentage of CD11c
-CD123
+ pDC decrease within the Lin
-HLA-DR
+ DC population following SSG 
monotherapy.  
 
Figure 4 Differences in the percentage of NK and NKTcells that produced perforin A. Fresh peripheral blood 
samples were evaluated by flow cytometry for the presence of NK and NKT cells with constitutive perforin A. (A) Perforin 
expression by NK cells is unaffected by SSG monotherapy (C1D8). Following treatment with both SSG and IFN- α 2b 
(C2D12), there is a significant increase in the percentage of NK cells expressing perforin A. (B) Similarly in CD3+16/56+ 
NKT cells, perforin A expression was unaffected by SSG monotherapy but was significantly increased by treatment with both 
SSG and IFN-α 2b (C2D12). 
 
 
Cytokine production by TLR-activated mDC and 
pDC  
In all patients at the end of SSG monotherapy 
(C1D8)  as  well  at  the  end  of  combination  therapy 
(C2D12), there were no significant changes in %mDC 
and %pDC that synthesized cytokines following ac-
tivation with the TLR agonist CL097 (data not shown). 
However, patients who received high-dose SSG had 
statistically significant increased median %pDC that 
synthesized IFN- following activation through TLR7 
and  TLR8  by  CL097  (3.15%  vs.  9.09%,  p  =  0.012). 
When IFN- 2b was added to this regimen, the per-
cent of pDC that produced IFN- increased further 
but not to statistical significance (9.09% vs. 12.98%, p = Journal of Cancer 2011, 2 
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0.0465). The syntheses of IL-10, IL-12, and TNF- by 
TLR-activated  mDC  remained  unchanged  with 
high-dose  SSG  monotherapy  or  following  combina-
tion therapy of high-dose SSG and IFN- 2b in both 
dose groups. Similarly, SSG alone or in combination 
with  IFN-  2b  did  not  affect  the  ability  of 
TCR-activated CD4+ T and CD8+ T cells to synthesize 
cytokines.  
Expression of granzyme B and perforin A by NK, 
NKT, and CD8
+ T cells 
NK, NKT and CD8+ T cells mediate tumor cell 
cytotoxicity  through  expression  of  granzyme  B  and 
perforin A. Data on all patients show that SSG alone 
did  not  affect  the  expression  of  perforin  A  and 
granzyme B in NK, NKT, and CD8+ T cells. Following 
the addition of IFN- 2b, there was a statistically sig-
nificant  increase  in  median  %NK  cells  (62.4%  vs. 
68.8%, p = 0.038) (Figure 4A) and median %NKT cells 
(7.4% vs. 18.0%, p = 0.006) (Figure 4B), but not in me-
dian CD8+ T cells expressing perforin A. Patients re-
ceiving  high-dose  SSG  and  IFN-  2b  had  a  higher 
%NK cells expressing perforin A (66.5% vs. 75.6%, p = 
0.028). No differences were observed in expression of 
granzyme B by NK, NKT, and CD8+ T cells of patients 
at either dose of SSG.  
DISCUSSION 
This  phase  I  study  investigated  the  biological 
activity of SSG in combination with IFN- 2b to de-
termine  toxicity  profile,  MTD,  and  immune  system 
effects. All patients had multiple prior treatments. No 
clinical responses were observed, despite the known 
biological activity of SSG in a number of animal ex-
perimental systems [17] where SSG alone or in com-
bination with IFN- 2b, demonstrated antitumor ac-
tivity against prostate cancer xenografts [18]. In an-
other experiment of SSG plus IL-2, antitumor activity 
against  renal  cell  carcinoma  in  mice  was  enhanced 
and  mediated  through  an  immune  mechanism  in-
volving IFN- [19].  
Common toxicities included asymptomatic ele-
vated serum lipase, thrombocytopenia, fatigue, fever, 
chills  and  anemia.  The  DLT  were  hypokalemia, 
thrombocytopenia, fatigue, pancreatitis and skin rash. 
Patients who received high-dose SSG had a sta-
tistically significant decrease in the median percent-
age of pDC at the end of SSG monotherapy with a 
concomitant  statistically  significant  increase  in  the 
median percentage of pDC that produced IFN-. At 
the end of cycle 2, day 12, the median percentages of 
pDC  and  pDC  producing  IFN-  were  increased. 
Plasmacytoid  dendritic  cells  are  the  most  potent 
producers of IFN- [20-22]. They greatly influence the 
differentiation of CD4+ T cells towards TH2 responses 
by producing IL-10 and inhibiting the production of 
IL-12 by mDC [23], or enhancing the development of 
TR  cells,  which,  in  turn,  suppresses  antigen-specific 
immune responses [24]. Conversely, IL-12 production 
by mDC enhances IFN- produced by T cells and NK 
cells and favors a TH1 immune response [25]. Here, 
low-dose SSG increased pDC activity as measured by 
the  increased  median  percentage  of  TLR-activated 
pDC that produced IFN-.  
IFN-  also  stimulates  mDC  to  stimulate  IL-12, 
which in turn stimulates T-cells to secrete IFN-, and 
arms  NK  cells  and  CD8+  cytotoxic  T  lymphocytes 
(CTL)  with  perforin  A  and  granzyme  B  for  killing 
tumor  targets.  However,  increased  production  of 
IFN- by pDC after SSG monotherapy were insuffi-
cient  to  induce  expression  of  perforin  A  by  NK  or 
NKT cells. Only after IFN- 2b administration did the 
median percentages of NK cells and NKT cells that 
expressed perforin A increase. Thus, the combination 
of SSG and IFN- 2b was necessary to induce expres-
sion of perforin A by these innate immune cells.  
Whereas NK cell activity is associated with in-
nate  immunity,  CD8+  CTL  is  required  for  adaptive 
immunity.  Sustained  adaptive  immunity  depends 
upon the production of IL-2 by activated CD4+ T cells 
to sustain T-cell proliferation and the production of 
IFN- by activated macrophages to co-stimulate CD8+ 
CTL. As TR cells inhibit the production of IL-2 by ac-
tivated T cells [26], the reduction in TR activity is de-
sirable  for  an  adequate  antitumor  response.  In  the 
current  study,  administration  of  low-dose  and 
high-dose SSG alone yielded significantly lower per-
centages  of  TR  cells.  However,  IL-2  production  by 
TCR-activated T cells was observed only in patients 
receiving high-dose SSG, and only after adding IFN- 
2b. Activation of TR cells inhibits production of IL-2 by 
activated T cells [26]. Although we did not measure 
circulating  levels  of  IFN-,  we  measured  IL-12  pro-
duced by mDC following activation through the TLR. 
IL-12 is responsible for inducing IFN- by T cells and 
NK cells [25]. Unfortunately, SSG alone and in com-
bination with IFN- 2b failed to significantly augment 
the percentage of TLR-activated mDC that produced 
IL-12. This may account for the lack of IFN- produc-
tion by T cells and the resultant lack of antitumor ac-
tivity  in  our  patients.  Others  reported  increases  in 
plasma levels of IFN- and in the percentage of CD4+ 
T cells that were capable of producing IFN- [27] as 
well as increased IFN- mRNA expression by alveolar 
macrophages  following  SSG  administration  [28]  in 
mice.  Journal of Cancer 2011, 2 
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This study was limited by the lack of a cohort 
that  received  IFN-  2b  prior  to  SSG,  which  would 
have permitted comparing IFN- 2b and SSG as sin-
gle agents, thereby helping to determine the optimal 
immune modulatory effect of these two drugs. This 
was  not  done  because  of  limitations  inherent  in  a 
phase I study.  
In conclusion, SSG in combination with IFN- 2b 
was well tolerated at 900 mg/m2 and demonstrated 
immune  modulation.  There  was  an  increase  in  the 
proportion of TLR7- and TLR8-activated pDC in pa-
tients receiving high-dose SSG that produced IFN-. 
These data represent increased adaptive and innate 
immune responses following therapy with high-dose 
SSG in combination with IFN- 2b. 
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